Venus Remedies Limited has announced that its Board of Directors will meet on January 29, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company issued the notice on January 19, 2026, informing stock exchanges about the upcoming board meeting.

Board Meeting Agenda

The board meeting has been scheduled with specific objectives for the quarter ended December 31, 2025. The meeting will address key financial matters and any additional business items that may arise.

Trading Window Restrictions

In accordance with regulatory requirements, Venus Remedies Limited has implemented trading restrictions for designated persons. The company has closed the trading window as part of its compliance with Prevention of Insider Trading regulations.

The trading window closure ensures that individuals with access to unpublished price-sensitive information cannot trade in the company's shares during the restricted period. This measure protects market integrity and ensures fair disclosure of financial information to all stakeholders.

Company Communication

The notice was signed by Neha, Company Secretary with membership number F8374, and was digitally signed on January 19, 2026. The communication was sent to both the National Stock Exchange of India Limited and BSE Limited, where the company's shares are listed under script codes VENUSREM and 526953 respectively.

The board meeting represents a routine quarterly disclosure requirement, allowing the company to share its financial performance with investors and stakeholders in a transparent manner.

Venus Remedies Limited has issued a regulatory update regarding the correction of UDIN (Unique Document Identification Number) for its financial results for the quarter ended September 30, 2025. The pharmaceutical company identified and rectified a clerical error in the auditor identification numbers used in its quarterly financial reporting.

UDIN Correction Details

The company's statutory auditors inadvertently used the same UDIN in both standalone and consolidated limited review reports, when separate identification numbers should have been generated for each report type. The correction addresses this administrative oversight to ensure proper regulatory compliance.

The company clarified that two separate UDINs were duly generated for the standalone and consolidated limited review reports, and the duplication was purely clerical in nature. This administrative correction does not impact the financial data or results previously reported.

Regulatory Compliance

Venus Remedies has resubmitted the complete set of financial results with the correct UDIN to both BSE Limited and National Stock Exchange of India Limited. The correction ensures compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company's communication was signed by Neha, Company Secretary (M. No. F8374), and digitally authenticated on January 13, 2026. This correction demonstrates the company's commitment to maintaining accurate regulatory documentation and transparency in its financial reporting processes.

Company Operations

Venus Remedies Limited operates multiple manufacturing units across India and Germany, with its registered office in Chandigarh and corporate office in Panchkula, Haryana. The company maintains certifications including AEO (Authorized Economic Operator) status with Indian Customs and operates as a Responsible Export Organization.